Impax Laboratories Taiwan Sells Share Capital and Loans for $18,500,000 to Bora Pharmaceuticals Co. Ltd.

February 5, 2018

S&C client Impax Laboratories, Inc., a leading specialty pharmaceutical company, completed their previously announced sale of all of the issued share capital in Impax Laboratories (Taiwan), Inc. and certain loans outstanding between Impax and Impax Taiwan for a purchase price of $18,500,000 pursuant to a stock and asset purchase agreement with Bora Pharmaceuticals Co. Ltd., a Taiwan corporation. Bora and Impax Taiwan will supply certain generic marketed and pipeline pharmaceutical products to Impax pursuant to a supply agreement. 

The S&C team advising Impax was led by Frank Aquila, along with Jinhee Chung, Amanda Gill, Ashlyann Harrison and Lu Ma. Ron Creamer and Dana Brodsky advised on tax matters; Nader Mousavi, along with Justin Orr and Mark Schenkel, advised on intellectual property matters; Matthew Brennan advised on environmental matters; and Heather Coleman, along with Joshua Green, advised on executive compensation and benefits matters.